By: IPP Bureau
Last updated : November 27, 2021 11:33 am
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
The government has selected 55 manufacturers in three categories out of 278 applications received under the PLI Scheme for the pharmaceutical sector.
The scheme covers three different product categories for which applicants have applied under the scheme. These products are expected to give an impetus to innovation, R&D and widening of the product profile of the India Pharmaceutical industry.
In Group A, 11 companies were selected. The category comprises Biopharmaceuticals; Complex generic drugs; Patented drugs or drugs nearing patent expiry; Cell-based or gene therapy drugs; Orphan drugs; Special empty capsules like HPMC, Pullulan, enteric etc.; Complex excipients; and Phyto-pharmaceuticals.
In Group B, 9 companies were selected. The category comprises Active Pharmaceutical Ingredients/Key Starting materials/Drug Intermediates (except the Active Pharmaceutical Ingredients/Key Starting materials/Drug Intermediates covered under the earlier PLI scheme for APIs/KSMs and DIs being implemented by the department).
Selected Manufacturers in Group A
1. Sun Pharmaceutical Industries Limited
2. Aurobindo Pharma Limited
3. Dr. Reddy’s Laboratories Limited
4. Lupin Limited
5. Mylan Laboratories Limited
6. Cadila Healthcare Limited
7. Cipla Limited
8. Amneal Pharmaceuticals Private Limited
9. Glenmark Pharmaceuticals Limited
10. Intas Pharmaceuticals Limited
11. Torrent Pharmaceuticals Limited
Selected Manufacturers in Group B
1. Biocon Limited
2. MSN Laboratories Private Limited
3. Wockhardt Limited
4. Alembic Pharmaceuticals Limited
5. Emcure Pharmaceuticals Limited
6. Macleods Pharmaceuticals Ltd.
7. Biological E Limited
8. Natco Pharma Limited
9. Strides Pharma Science Limited
Selected Manufacturers in Group C
1. Vindhya Pharma (India) Private Limited
2. Aarti Industries Limited
3. Symbiotec Pharmalab Private Limited
4. Transasia Bio-Medicals Limited
5. Sai Life Sciences Limited
6. Poly Medicure Limited
7. Concord Biotech Limited
8. Amoli Organics Private Limited
9. BDR Pharmaceuticals International Private Limited
10. Malladi Drugs & Pharmaceuticals Limited
11. Symed Labs Limited
12. Bal Pharma Limited
13. Acme Formulation Private Limited
14. Panacea Biotec Limited
15. Abhilash Life Sciences LLP
16. Neogen Chemicals Limited
17. Biophore India Pharmaceuticals Private Limited
18. Nosch Labs Private Limited
19. Aragen Life Sciences Private Limited
20. Sri Krishna Pharmaceuticals Limited
21. Optimus Drugs Private Limited
22. Venus Remedies Limited
23. Psychotropics India Limited
24. Steril-Gene Life Sciences Private Limited
25. Aurore Life Sciences Private Limited
26. Milan Laboratories India Private Limited
27. Vandana Life Science Private Limited
28. Nitika Pharmaceutical Specialities Private Limited
29. Hy-Gro Chemicals Pharmtek Private Limited
30. Mendas Pharma Private Limited
31. Optimus Pharma Private Limited
32. Maiva Pharma Private Limited
33. Trivitron Healthcare Private Limited
34. Agappe Diagnostics Limited
35. Premier Medical Corporation Private Limited
In Group C, 35 companies were selected of which 20 are MSMEs. The category comprises Repurposed drugs; Autoimmune drugs, anti-cancer drugs, anti-diabetic drugs, anti-infective drugs, cardiovascular drugs, psychotropic drugs and antiretroviral drugs; In vitro diagnostic devices; Other drugs not manufactured in India.
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme. The selection of applicants in each of the three categories has been approved by the Minister for Chemicals and Fertilizers.
With this announcement, a major thrust in investment is expected by the pharmaceutical industry which is ultimately aimed at meeting the objectives of the scheme.
The objective of the scheme is to enhance India’s manufacturing capabilities by increasing investment and production in the sector and contributing to product diversification to high-value goods in the pharmaceutical sector. One of the further objectives of the scheme is to create global champions out of India who has the potential to grow in size and scale using cutting edge technology and thereby penetrate the global value chains.